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Predictors of Invasive Breast Cancer in Ductal
Carcinoma In Situ Initially Diagnosed by Core Biopsy
Mun Yew Patrick Chan and Serene Lim, The Breast Clinic, Tan Tock Seng Hospital, Singapore.
BACKGROUND: Some patients who are initially diagnosed with ductal carcinoma in situ (DCIS) by core
biopsy eventually have their disease upstaged to invasive carcinoma on final excision, thus warranting
some form of axillary staging. This study aimed to identify the predictors of invasive breast cancer in
DCIS diagnosed by core biopsy, which could then help clinicians decide which cases of biopsy-diagnosed
DCIS should undergo concurrent sentinel lymph node biopsy during excision.
METHODS: The records of 95 consecutive patients diagnosed with pure DCIS from 100 core biopsies
from January 2005 to August 2007 were retrospectively reviewed. The clinical, radiological and pathological
characteristics of these 100 cases were correlated with the presence of invasion or microinvasion on excision.
RESULTS: Factors that are associated with invasive or microinvasive foci on excisional histology are: size
of target lesion on radiography ≥ 20 mm [odds ratio: 6.738 (1.050–43.236), p = 0.044] and ≤ 10 cores
obtained [odds ratio: 22.343 (2.351–212.385), p = 0.007].
CONCLUSION: Underestimation of invasive breast cancer in core biopsy–diagnosed DCIS is related to
the size of the lesion on radiography, as well as the number of cores obtained during biopsy. [Asian J Surg
2010;33(2):76–82]
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Introduction
Ductal carcinoma in situ (DCIS) is the proliferation of
malignant ductal epithelial cells within the confines of
the ductal epithelial basement membrane, and commonly
presents as mammographic calcifications. In the Singapore
Breast Screening Project, DCIS accounted for 26% of
breast cancers detected through screening.1
When DCIS is diagnosed by core biopsy, there is a sig-
nificant underestimation of invasion from within the
lesion.2–9 Axillary staging is not indicated in DCIS per se,
because the prevalence of sentinel lymph node (SLN) meta-
stases in pure DCIS is extremely low,10,11 and even if posi-
tive, the SLN is usually the only lymph node involved.10–12
Moreover, although generally regarded as safe, SLN biopsy
is not completely risk-free. Potential complications in-
clude allergic reaction to the dye used, lymphoedema and
injury to the intercostobrachial nerves. With current tech-
nology, SLN biopsy is indicated for patients with DCIS
who require mastectomy,12,13 because the chance for SLN
biopsy would be lost if the mastectomy specimen were
found to harbour invasive carcinoma. In cases in which
DCIS is upgraded to invasive carcinoma, a second op-
eration for staging can be avoided if SNL biopsy is done
concurrently with primary surgical excision.
The present study aimed to identify the predictors of
occult invasive breast cancer in DCIS diagnosed by core
biopsy; these predictors could help to better identify
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patients who should have concurrent SLN biopsy during
excision.
Patients and methods
The database of the Breast Clinic at Tan Tock Seng
Hospital, Singapore showed that a total of 109 patients
were diagnosed with DCIS by core biopsy at our institution
from January 2005 to August 2007. The clinical, radiologi-
cal and pathological records of these patients were retro-
spectively reviewed. Those with findings of microinvasion,
definite invasion or equivocal invasion were excluded.
Clinical factors assessed were age and menstrual sta-
tus at diagnosis, presence of a palpable mass, and size of the
mass. Radiological factors were evaluated according to
whether the target lesion was in the form of calcifications
or a radiological (mammographic and/or sonographic)
mass. The size of the target lesion on radiography was also
assessed. Breast Imaging Reporting and Data System
(BIRADS) (mammogram and ultrasound) scores were com-
puted according to the American College of Radiology
mammogram and ultrasound BIRADS guidelines. A low
BIRADS score is 2 or 3 and a high score is 4 or 5.
All patients underwent one of the following core biopsy
methods: freehand core needle biopsy for grossly palpa-
ble lesions (11%), conventional stereotactic (6%) or ultra-
sound-guided (32%) core needle biopsy using a 14G Bard
Magnum biopsy gun (Bard Peripheral Vascular Inc., Tempe,
AZ, USA), or vacuum-assisted core biopsy (51%) using an
11G Mammotome needle (Ethicon Endo-Surgery Inc.,
Cincinnati, OH, USA). The decision to use stereotactic
core biopsy or mammotomy depended largely on the
extent of the microcalcifications, with the latter being
favoured when the extent of microcalcifications was small.
The number of cores sampled was recorded. All stereotactic
biopsies for calcifications were accompanied by a speci-
men radiograph that demonstrated capture of the target
lesion in the specimen. Biopsy specimens were processed
with haematoxylin and eosin stain, and if needed, addi-
tional stains for cytokeratin 5/6 and p63 were employed.
Histological features assessed included grade, histologi-
cal type, type of necrosis (comedo vs. noncomedo), intra-
luminal calcifications, and lobular cancerization.
Following core biopsy diagnosis of DCIS, all patients
underwent surgical excision in the form of simple mastec-
tomy or wide excision, with or without SLN biopsy. All
patients (with the exception of one who defaulted from
further follow-up) with involved or close (< 1 mm) mar-
gins underwent re-excision or mastectomy until clear mar-
gins were achieved. Cases were dichotomized into DCIS
and invasive groups, by taking into account histology
results from all excision and re-excision specimens. The
invasive group also included cases of microinvasion. The
DCIS group included cases in which no residual DCIS
was found on excision histology.
Statistical analysis was performed using SPSS version
11.5 (SPSS Inc., Chicago, IL, USA). Univariate analysis was
done using the χ2 test and logistic regression. Continuous
variables were delineated into two subgroups using the
population median as the cut-off. Multivariate logistic
regression was also performed for significant variables.
All variables were considered significant when p was < 0.05.
Results
A total of 112 core biopsies with a diagnosis of DCIS were
performed on 109 patients. Twelve core biopsies were
excluded because of equivocal findings of invasion or
microinvasion. One hundred cases of pure DCIS were in-
cluded in the study (Table 1). Of these, 19 (19%) were
upstaged to invasive carcinoma on final excision, 2 (2%)
cases were found to have definite microinvasion, and 2 (2%)
were found to have equivocal microinvasion on final 
histology. In the latter two cases, one was found to have
possible microinvasion, and in the other, microinvasion
was not assessable. Cases with microinvasion or equivocal
microinvasion without evidence of frank invasion were
included in the invasive group for analysis, because one
would tend to err on the side of caution and offer axillary
staging to such patients, compared with patients whose
excisional histology revealed pure DCIS. This constituted
a total of 23 (23%) cases in the invasive group.
All patients (with the exception of two) who were diag-
nosed with invasion, microinvasion or equivocal microin-
vasion on excisional histology underwent axillary staging
in the form of SLN biopsy or axillary clearance. Two
patients were eventually found to have positive axillary
lymph nodes. In one patient, micrometastasis was pres-
ent in one of the eight lymph nodes. In the other patient,
metastatic involvement was found in 6 of the 22 lymph
nodes sampled. Both patients had evidence of definite
invasive carcinoma on excisional histology. None of the
patients who were diagnosed with pure DCIS on final
excision were found to have positive axillary or SLNs.
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Factors that significantly predict upstaging of DCIS
to invasive carcinoma on final excision are size of target
lesion on radiography ≥ 20 mm [odds ratio (OR): 6.738
(1.050–43.236), p = 0.044] and ≤ 10 cores obtained [OR:
22.343 (2.351–212.385), p = 0.007] on multivariate analy-
sis (Table 2).
Discussion
DCIS can be diagnosed by a variety of methods with dif-
fering levels of accuracy. Fine needle aspiration does not
reliably differentiate in situ from invasive carcinoma,14,15
and is unable to characterize further the lesion histologi-
cally even if carcinoma is diagnosed, therefore, it is generally
not used in the routine diagnosis of DCIS. Open surgical
biopsy is considered the gold standard for diagnosis of
impalpable breast lesions, but its use has increasingly been
replaced by percutaneous core-needle biopsy. Compared
with open surgical biopsy, percutaneous core-needle bio-
psy is reported to be safer, more cost-effective, less psycho-
logically distressing and less disfiguring; it also produces
less radiological scarring, which can interfere with future
imaging.16
Currently, there are several different forms of core-
needle biopsy. Freehand core biopsy for grossly palpable
masses can be conveniently done in the office setting. For
nonpalpable breast lesions, image-guided core biopsy
methods are available, and these include conventional
stereotactic or ultrasound-guided core biopsy, as well 
as newer vacuum-assisted biopsy. The sensitivity and
Table 1. Characteristics of patients with initial diagnosis of ductal
carcinoma in situ
Variable
No. of biopsies
(n = 100)
Age (yr) 31–85 (mean: 54.7)
Menstrual status (95 patients)
Premenopausal 43
Postmenopausal 52
Presence of palpable lump
No 69
Yes 31
Type of target lesion on 
mammogram
Calcifications 61
Radiological mass 34
Architectural distortion 5
Size of target lesion on 
radiography (mm)
< 10 32
10–19 24
20–29 34
≥ 30 10
Mammographic BIRADS score
Low (2 or 3) 15
High (4 or 5) 85
Ultrasound BIRADS score
Low (2 or 3) 13
High (4 or 5) 55
Biopsy method
Free hand core biopsy 11
Ultrasound-guided core biopsy 32
Stereotactic core biopsy 6
Stereotactic mammotomy 51
No. of cores
≤ 5 9
6–10 cores 35
> 10 cores 56
Grade of DCIS on core biopsy
Low 1
Intermediate 9
High 61
Not specified 29
Type of DCIS*
Cribriform 37
Papillary 24
Solid 26
Not specified 36
(Contd)
Table 1. Continued
Variable
No. of biopsies
(n = 100)
Presence of intraluminal calcifications
No 69
Yes 31
Presence of necrosis
No necrosis 62
Noncomedo necrosis 5
Comedonecrosis 33
Presence of lobular cancerization
No 86
Yes 14
*Some biopsies had more than one type of DCIS described.
BIRADS = breast imaging reporting and data system; DCIS = ductal
carcinoma in situ.
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specificity of conventional percutaneous core-needle bio-
psy can reach up to 97% and 100%, respectively.2,3,5,15 How-
ever, conventional percutaneous core-needle biopsy has
an inherent problem of sampling error, which contributes
to a significant DCIS underestimation rate (i.e. percent-
age of DCIS cases that are eventually found to harbour
invasive foci), which can range from 14% to as high as
50%2–9 for stereotactic core-needle biopsy. In addition,
core-needle biopsy generally does not sample microcalci-
fications well, which leads to a greater underestimation
rate than if the lesion were a mass.
Vacuum-assisted biopsy enables a greater amount of
tissue to be removed with minimal passes, and was intro-
duced in an attempt to reduce sampling error, and there-
fore, the misdiagnosis rates of stereotactic core-needle
biopsy. DCIS underestimation rates for vacuum-assisted
biopsy are in the range of 4–18%.2,9,15,16
The inherent sampling error present in all forms of per-
cutaneous core-needle biopsy, including vacuum-assisted
biopsy, forms the basis for the use of SLN biopsy in the
management of what is considered to be a preinvasive dis-
ease with no metastatic potential. Inclusion of SLNs in
the surgical excision of DCIS helps to preempt the possi-
bility that a lesion that is thought to be pure DCIS on
core biopsy can be an invasive cancer when excised, and
might even be node-positive cancer. This potentially elim-
inates the need for additional surgery in the form of axil-
lary staging should invasive carcinoma be detected on
final excision. One study has also suggested that SLNs
can help improve the detection of occult invasive/microin-
vasive foci in the excision specimen.17 The detection of 
a positive SLN in a excision specimen that was initially
diagnosed as pure DCIS can trigger reassessment of the
specimen for invasive/microinvasive foci, and thus help
to stage and further manage the disease appropriately.
In our study, the rate of upstaging of DCIS initially
diagnosed on core biopsy to definite unequivocal invasive/
microinvasive carcinoma on final excision was 21%. Our
Table 2. Analysis of predictors of invasive breast cancer in core biopsy–diagnosed ductal carcinoma in situ using univariate and multi-
variate logistic regression models
Univariate logistic regression Multivariate logistic regression
Variable
OR (95% CI) p OR (95% CI) p
Age ≥ 50 yr 2.015 (0.716–5.673) 0.185 – –
Postmenopausal 2.346 (0.868–6.340) 0.093 – –
Presence of palpable lump 3.005 (1.135–7.955) 0.027 – –
Radiological mass as target lesion 4.687 (1.741–12.619) 0.002 – –
Size of target lesion on radiography ≥ 20 mm 3.103 (1.172–8.220) 0.023 6.738 (1.050–43.236) 0.044
Low mammographic BIRADS score 1.489 (0.418–5.307) 0.539 – –
High ultrasound BIRADS score 2.895 (1.056–7.941) 0.039 – –
Trucut biopsy 3.984 (1.415–11.219) 0.009 – –
≤ 10 cores obtained 7.962 (2.433–26.049) 0.001 22.343 (2.351–212.385) 0.007
High grade DCIS on core biopsy 0.958 (0.377–2.434) 0.928 – –
Type of DCIS on core biopsy – –
Absence of cribriform histology 5.271 (1.445–19.230) 0.012
Presence of papillary histology 1.157 (0.397–3.372) 0.790
Presence of solid histology 0.741 (0.244–2.249) 0.596
Presence of necrosis on core biopsy
Noncomedo necrosis 0.719 (0.075–6.915) 0.775 – –
Comedonecrosis 0.639 (0.223–1.829) 0.404
Presence of intraluminal calcifications 0.652 (0.216–1.968) 0.448 – –
Presence of lobular cancerization 1.411 (0.398–5.005) 0.595 – –
OR = odds ratio; CI = confidence interval; BIRADS = breast imaging reporting and data system; DCIS = ductal carcinoma in situ.
■ CHAN & LIM ■
80 ASIAN JOURNAL OF SURGERY VOL 33 • NO 2 • APRIL 2010
rate, from an Asian population, appears similar to those
reported in other studies from western countries.2–6 Two
factors were found to be significantly associated with
invasive or microinvasive foci on mastectomy or wide exci-
sion: size of target lesion on radiography ≥ 20 mm [OR:
6.738 (1.050–43.236), p = 0.044] and ≤ 10 cores obtained
on core biopsy [OR: 22.343 (2.351–212.385), p=0.007], with
rates of underestimation of 34.1% and 40.9%, respectively.
To the best of our knowledge, at least four other stud-
ies have demonstrated a relationship between target lesion
size and risk of upstaging of DCIS diagnosed on core
biopsy. In the study by Renshaw,18 aggregate size and size
of the largest focus by themselves were not significant for
predicting invasion on excisional histology (p > 0.05), but
the combination of aggregate size > 4 mm with lobular
extension was associated with the detection of invasion
on final histology (p = 0.03). Huo et al19 have reported
that lesion size > 1.5 cm was significantly associated with
greater odds of upstaging to invasive carcinoma after
definitive surgery [OR: 3.15 (1.44–6.88), p = 0.0041]. The
study by Pandelidis et al16 on 140 lesions diagnosed as
either atypical ductal hyperplasia or DCIS by 11-gauge
vacuum-assisted biopsy found that, among the 91 lesions
initially thought to be DCIS, the underestimation rate
was highest in patients when the target lesion for biopsy
was a zone of calcification > 1.5 cm. In addition, Jackman
and Rodriguez-Soto20 have demonstrated a positive asso-
ciation between DCIS underestimation rate and increas-
ing maximum diameter of the target lesion. In their study,
the DCIS underestimation rate was 11.9% for lesions
1–10 mm, 14.6% for lesions 11–20 mm, and 21.9% for
lesions ≥ 21 mm in maximum diameter (p = 0.003).
Our finding that the number of cores obtained was
significantly correlated with the risk of invasive histology
on excision has been corroborated by Lee et al,9 who have
found that the DCIS underestimation rate was 11.5%
when > 10 specimens per lesion were obtained, compared
with 17.5% when ≤ 10 specimens per lesion were obtained
(p < 0.02). Pandelidis et al16 have recommended sampling
≥ 10 cores per lesion. The study by Jackman and Rodriguez-
Soto20 found that failure of 11-gauge vacuum biopsy to
retrieve nonpalpable microcalcifications was least com-
mon when 13–24 specimens were obtained. However, it
was also noted that the odds of retrieval failure actually
increased slightly for each additional specimen obtained,
and that this was significant when > 24 specimens were
retrieved. This was attributed to diminishing returns of
obtaining more than 24 specimens. It has been suggested
that there is little need to obtain > 12–18 specimens per
lesion unless initial specimen radiography fails to demon-
strate the target microcalcifications.
The observation that lesion size and number of cores
obtained are significant predictors of occult invasion on
final histology is not surprising. As previously mentioned,
the cause of DCIS underestimation on core biopsy is 
sampling error, whether by conventional stereotactic or
ultrasound-guided methods or by newer vacuum-assisted
biopsy. Therefore, any factor that affects sampling could
understandably have an impact on DCIS underestima-
tion rate. A larger target lesion increases the target surface
area for sampling, which gives rise to a greater probability
of sampling error. Similarly, a greater number of cores
sampled means that a greater volume of tissue from the
target lesion is removed, although a point would proba-
bly be reached at which additional removal of cores would
give no further benefit to the patient, as suggested by
Jackman and Rodriguez-Soto.20 The findings of our study
underscore the importance of adequate sampling of the
target lesion when making the correct diagnosis.
Several studies such as those by Huo et al19 and Goyal
et al21 have reported a correlation between the presence of
a mass (clinically or on imaging) and greater odds of upstag-
ing of DCIS on final excision. In our study the presence
of palpable and radiological masses was a significant pre-
dictor of occult invasion on univariate analysis (p = 0.027
and 0.002, respectively) but not on multivariate analysis.
Based on our univariate results, it appears that, if the tar-
get lesion is a radiological mass rather than a calcifica-
tion, there are greater odds of upstaging the lesion on
excision. In the same vein, it seems that radiological calci-
fications might have a “protective” effect against upstag-
ing. These results were not significant on multivariate
analysis but there appeared to be a trend in that direction,
by looking at the univariate analysis of the mammographic
and ultrasonographic BIRADS scores. Suspicious calcifi-
cations tend to be detected better on mammography and
thus increase the mammographic BIRADS score, whereas
suspicious masses tend to be seen more clearly on ultra-
sonography, which gives rise to a higher ultrasonographic
BIRADS score. On univariate analysis, a low mammo-
graphic BIRADS score [OR: 1.489 (0.418–5.307), p = 0.539]
and high ultrasound BIRADS score [OR: 2.895 (1.056–
7.941), p = 0.039] were both associated with greater odds
of finding occult invasion on final histology, although
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both variables were statistically insignificant on multi-
variate analysis.
In our study, biopsy method was not found to be a sig-
nificant predictor of occult invasion on multivariate analy-
sis. Nevertheless, our DCIS underestimation rate was
lower for mammotomy than for conventional core biopsy
methods (Table 3). This has been widely corroborated by
other studies.2,9,15,16 We looked at four patients with missed
microinvasive/invasive carcinoma and found that one
developed profuse bleeding during mammotomy and was
abandoned after only four cores. The other three patients
had 8–12 cores sampled. All three patients had relatively
small areas of microinvasive/invasive carcinoma in a com-
paratively large area of DCIS. All four patients had a nega-
tive SLN biopsy, although one was found to have detectable
lymphovascular invasion on excision.
In conclusion, both the size of the target lesion on radi-
ography and the number of cores obtained during biopsy
are significant predictors of invasive breast cancer in DCIS
diagnosed by core biopsy. Efforts should be made to obtain
> 10 cores on initial biopsy to avoid underestimation of
invasive cancer. Patients with large DCIS or a small number
of cores should be offered SLN biopsy. Vacuum-assisted
biopsy might help to reduce sampling error and therefore
the DCIS underestimation rate. This could influence selec-
tion of the method of preoperative diagnosis of DCIS.
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